TP53 and cancer: Over 50% of human CRCs are reported to have defective p53 expression ensued by a mutated TP53 gene and this defect often contributes to drug resistance, challenging the clinicians in devising chemotherapeutic strategies for management of cancer patients with this mutation (15, 37).